Poster - #UMDOM126 - Clinical Research and Quality Improvement

Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation

Jose F Camargo, MD (1), Maria A. Mendoza, MD (2) , Rick Lin (2) , Ilona V. Moroz (1) , Anthony D. Anderson (3), Michelle I Morris, MD (1), Yoichiro Natori, MD (1), Akina Natori, MD (4), Mohammed Raja, MD (1), Lazaros Lekakis , MD (5), Amer Beitinjaneh, MD (5), Antonio Jimenez, MD (5), Mark Goodman, MD (5), Trent Wang, MD (5), Krishna V. Komanduri, MD (5), Denise Pereira, MD (5)

(1) Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA. (2) Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. (3) Department of Pharmacy, Sylvester Comprehensive Cancer Center, Miami, FL, USA. (4) Division of Medical Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL (5) Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL, USA

ABSTRACT
Retrospective cohort study of adult HCT recipients with SARS-CoV2 infection. 28 patients were identified. 12 (43%), 7 (25%) and 9 (32%) patients had mild, moderate and severe disease, respectively. 10 (53%) had documented virological clearance, with a median time to clearance of 34 days. Overall mortality was 25%, and exclusively seen in hospitalized patients, older than 50 years of age with severe COVID-19. Patients diagnosed with COVID-19 within 12 months of HCT exhibited higher mortality.